Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Dec 9;9(23):6218-6219.
doi: 10.1182/bloodadvances.2025017650.

Pharma steps back from Hodgkin lymphoma: now what?

Ryan C Lynch  1   2 , Ajay K Gopal  1   2
Affiliations
Editorial

Pharma steps back from Hodgkin lymphoma: now what?

Ryan C Lynch et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.K.G. reports research funding from Merck, I-Mab Biopharma, IGM Biosciences, Takeda, Gilead, AstraZeneca, Agios, Janssen, Bristol Myers Squibb, SeaGen, Teva, Genmab, BeiGene, Pfizer, and Umoja; consultancy/honoraria for Incyte, Kite, Morphosys/Incyte, ADC Therapeutics, Acrotech, Merck, Karyopharm, Servier, BeiGene, Cellectar, Janssen, Compliment, SeaGen, Epizyme, I-Mab Biopharma, Gilead, Genentech, Lilly, Caribou, Fresenius-Kabi, SciTech, Sana, Compliment, Incyte, Kite, ADC Therapeutics, Acrotech, Servier, BeiGene, Compliment, Genentech, Lilly, Caribou, Fresenius-Kabi, Scitek, and Sana; and owns stock options for Compliment Corporation and SciTech. R.C.L. reports research funding from TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, Pfizer, Rapt, Merck, Janssen, and Allogene; and consultancy/honoraria from SeaGen, AbbVie, Janssen, Merck, ADC Therapeutics, Foresight Diagnostics, and Genentech.

Comment on

  • Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
    Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor Á, Townsend W, André M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C. Herrera AF, et al. Blood Adv. 2025 Dec 9;9(23):6205-6217. doi: 10.1182/bloodadvances.2024015600. Blood Adv. 2025. PMID: 40811783 Free PMC article. Clinical Trial.

References

    1. Herrera AF, Ansell SM, Zinzani PL, et al. Camidanlumab tesirine in relapsed or refractory classic Hodgkin lymphoma: a phase. Blood Advances. 2025;9(23):6205–6217. - PubMed
    1. Richardson NC, Kasamon Y, Pazdur R, et al. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23(5):563–566. - PubMed
    1. ADC Therapeutics ADC Therapeutics announces US Food and Drug Administration has lifted partial clinical hold on pivotal phase 2 clinical trial of Camidanlumab tesirine. 2020. https://ir.adctherapeutics.com/press-releases/press-release-details/2020...
    1. ADC Therapeutics ADC Therapeutics reports third quarter 2022 financial results and provides business updates. 2022. https://ir.adctherapeutics.com/press-releases/press-release-details/2022...
    1. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. N Engl J Med. 2024;391(15):1379–1389. - PMC - PubMed